Home › Trial NCT02899286
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Trial IDNCT02899286
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorBio-Cancer Treatment International Limited
- Enrollment25
- Start date2016-09
- ConditionsAcute Myeloid Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.